Cohance Lifesciences Limited — Updates, 12-02-2025: Press Release

Suven Pharmaceuticals reported a strong performance for the third quarter and nine months, with a 40% year-on-year revenue growth on a proforma basis, reaching ₹6.76 billion. The Pharma CDMO segment led this growth, showcasing a remarkable 101% increase, driven by robust R&D and business development efforts. Adjusted EBITDA margins improved to 38.7%.

For the nine-month period, Suven's proforma revenues grew 5% to ₹17.7 billion, while standalone revenues reached ₹7.96 billion. Positive developments in their Pharma CDMO pipeline included a 2x increase in RFQs and the addition of two new Phase 3 molecules, elevating total active projects to 15.

Executive management expressed confidence in sustaining momentum and reaffirmed the target of achieving $1 billion in revenue, underpinned by their increasing CDMO share and strategic investments in niche technologies. With a positive outlook ahead, opportunities for expansion and innovation are anticipated as the company navigates the evolving market landscape.